Ashley I. Michnick, Sarah C. MacDonald, Austin Cosgrove, Sruthi Adimadhyam, Fang Zhang, Andrew B. Petrone, Katherine E. Round, Sampada Gandhi, Nana Koram, Olympia E. Anastasiou, Heather Rubino, Maria Maddalena Lino, Djeneba Audrey Djibo, Kuntz Jl, S B Love, Cheryl N. McMahill-Walraven, Kristin Palmsten, Anna E. Wentz, Judith C. Maro, Richard Platt, Susan E. Andrade
This interim analysis of an ongoing retrospective cohort study uses data from 5 US health plans to assess safety of a bivalent prefusion F subunit–based respiratory syncytial virus (RSV) vaccine administered during pregnancy during the first full RSV season after US Food and Drug Administration approval (from September 22, 2023, through June 14, 2024).